All In Biotech

Drug Trial Radar · NCT01095003

Trial of Vinflunine Plus Capecitabine in Advanced Breast Cancer

A Phase III Trial of Vinflunine Plus Capecitabine Versus Capecitabine Alone in Patients With Advanced Breast Cancer Previously Treated With or Resistant to an Anthracycline and Who Are Taxane Resistant.

Last checked: Nov 19, 2026Latest source record: Apr 28, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 770 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

770

Actual

Start

May 2009

Primary completion

Dec 2011

Study completion Oct 2015

Sponsor

Lead sponsor
Pierre Fabre MedicamentIndustry
Sponsor type
Industry
First posted
Mar 29, 2010

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
Female only, from 21 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The increasing use of anthracyclines and taxanes in the adjuvant, neoadjuvant and first-line metastatic settings, led to a raise of patients presenting with metastatic breast cancer after treatment with these agents. Options for the treatment of patients who have progressed after an anthracycline and a taxane are limited. The high level of in-vitro synergy of vinflunine combined with 5-fluorouracil (5-FU) together with the good tolerance and the encouraging response rate observed while combining IV vinflunine to oral capecitabine make it a promising combination to investigate further in a phase III trial. This phase III trial will evaluate the effectiveness and the safety profile of such combination for the treatment of patient with advanced breast cancer previously treated with or resistant to anthracycline and taxane resistant.

Conditions

  • Breast Cancer

Interventions

  • Vinflunine plus CapecitabineDrug

    Vinflunine 280mg/m² as a 20-minute i.v. infusion on day 1 of each cycle repeated every 3 weeks Capecitabine 825mg/m² per os twice per day for 14 consecutive days starting day 1 of each cycle repeated every 3 weeks

  • CapecitabineDrug

    Capecitabine 825mg/m² per os twice per day for 14 consecutive days starting day 1 of each cycle repeated every 3 weeks

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression Free SurvivalTime frame: Baseline up to 2 years 7 months

Locations

110 sites in 21 countries. Site status is shown where the registry gives one.

  • Site not named

    Buenos Aires, Argentina

  • Site not named

    Quilmes, Argentina

  • Site not named

    Rosario, Argentina

  • Site not named

    San Martin, Argentina

  • Site not named

    San Miguel de Tucumán, Argentina

  • Site not named

    Grodno, Belarus

  • Site not named

    Homyel, Belarus

  • Site not named

    Minsk, Belarus

  • Site not named

    Vitebsk, Belarus

  • Site not named

    Brussels, Belgium

  • Site not named

    Liège, Belgium

  • Site not named

    Curitiba, Brazil

  • Site not named

    Porto Alegre, Brazil

  • Site not named

    Santo André, Brazil

  • Site not named

    São Paulo, Brazil

  • Site not named

    Plovdiv, Bulgaria

  • Site not named

    Sofia, Bulgaria

  • Site not named

    Stara Zagora, Bulgaria

  • Site not named

    Brno, Czechia

  • Site not named

    Jihlava, Czechia

  • Site not named

    Tallinn, Estonia

  • Site not named

    Angers, France

  • Site not named

    Caen, France

  • Site not named

    Dijon, France

  • Site not named

    Le Mans, France

  • Site not named

    Lorient, France

  • Site not named

    Lyon, France

  • Site not named

    Montpellier, France

  • Site not named

    Nantes, France

  • Site not named

    Saint-Brieuc, France

  • Site not named

    Saint-Cloud, France

  • Site not named

    Saint-Herblain, France

  • Site not named

    Tours, France

  • Site not named

    Villejuif, France

  • Site not named

    Budapest, Hungary

  • Site not named

    Székesfehérvár, Hungary

  • Site not named

    Szolnok, Hungary

  • Site not named

    Bangalore, India

  • Site not named

    Bhopal, India

  • Site not named

    Calicut, India

Showing 40 of 110 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.